ReviewAnnals of translational medicine2023
Detection of anti-ganglioside antibodies in Guillain-Barré syndrome.
Review in Annals of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- A systematic review of CRISPR applications in demyelinating peripheral nervous system disorders.Regenerative medicine · 2025Pooled it
- Congenital Disorders of Glycosphingolipid Biosynthesis: Ultrarare Severe Syndromes or Relatively Frequent Mild Neurocognitive Illnesses?Biomedicines · 2026Article
- An Assessment of Anti-Ganglioside Antibodies for the Diagnosis of Avian Ganglioneuritis and Potential Correlation with Gross Lesions, Microscopic Findings and Serologic Titers in Cockatiels Challenged with Parrot Bornavirus.Animals : an open access journal from MDPI · 2026Article
- Varicella-zoster virus infection triggering GD3 antibody-positive variant Guillain-Barré syndrome: a case report and literature review.BMC neurology · 2026Review
- The EGR1/ZFP36 axis governs glycosphingolipid metabolic reprogramming in monocyte-derived macrophages in guillain-barré syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- The Differential Diagnosis of Coma in the ICU: Hyperacute Postoperative Guillain-Barré Syndrome-A Case Report.Clinical case reports · 2026Article
- α2-3-sialylated glycosphingolipids in neuroinflammation, immunity, and programmed cell death: mechanistic evidence and context-dependent regulation: a comprehensive review.Frontiers in immunology · 2026Review
- Review
- Frequency of anti-GQ1b IgG antibody in Miller Fisher syndrome: a Chinese single center study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- A case report of zoster-induced Guillain-Barré syndrome: diagnostic challenges and potential role of pulse prednisone.Annals of medicine and surgery (2012) · 2025Article
- Pathologic and Therapeutic Schwann Cells.Cells · 2025Review
- Synthesis and Immunogenicity of Pseudo-Oligosaccharides Structurally Related to Repeating Units of Capsular Phosphoglycans of Human Pathogens.Molecules (Basel, Switzerland) · 2025Review
- Article
- Neurolymphomatosis mimicking a Guillain-Barré syndrome triggered by COVID-19 vaccination.Neuropathology : official journal of the Japanese Society of Neuropathology · 2025Article
- Unique Clinical and Psychiatric Challenges in Elderly Patients With Guillain-Barré Syndrome: A Case Series.Cureus · 2024Article
- Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.Journal of neurology · 2024Article
- Antiganglioside antibody frequency in routine clinical care settings.European journal of neurology · 2024Article
- Blockade of Rho-associated kinase prevents inhibition of axon regeneration of peripheral nerves induced by anti-ganglioside antibodies.Neural regeneration research · 2024Article
- Potential clinical implications of molecular mimicry-induced autoimmunity.Immunity, inflammation and disease · 2024Review
- Case report: Bilateral facial palsy with paresthesias and positive anti-GT1a antibodies.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gangliosides are a class of glycosphingolipid molecules that are highly enriched in cellular membranes of the nervous system. The gangliosides associated with autoimmune diseases of the nervous system are mainly GM1, GD1a, GalNAc-GD1a, GM1b, GD3, CD1b, GT1a, and GQ1b. Multiple antibodies recognizing gangliosides are associated with some acute or chronic peripheral neuropathies, especially Guillain-Barré syndrome (GBS) and its clinical variants. Antibodies binding to gangliosides can activate complement system and recruit macrophages on the axolemma at the nodes of Ranvier of motor fibers, which are found in the course of GBS, causing axonal degeneration and reversible conduction block or conduction failure. Testing of anti-gangliosides autoantibodies is helpful for diagnosis of autoimmune peripheral neuropathies or support the diagnosis of the subtypes. These anti-gangliosides antibodies are usually detected by several qualitative or quantitative methods, particularly enzyme-linked immunosorbent assay (ELISA) and immunodot assays, which have been commercialized or established in-house worldwide. Herein, we introduce the methods and clinical applications of these assays in the diagnosis of autoimmune peripheral neuropathies. Anti-gangliosides antibodies are diagnostic markers of GBS subtypes. We use GBS as an example to explain the role of anti-gangliosides antibodies in the pathogenesis and diagnostic classification of neuropathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.